Could a common diabetes drug melt heart fat and boost cardiac function?

NCT ID NCT02042664

Completed Disease control Sponsor: Assistance Publique Hopitaux De Marseille Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether GLP-1 receptor agonists, a type of diabetes drug, can improve heart function and reduce fat around the heart in 44 obese adults with type 2 diabetes. Participants received the drug BYETTA along with metformin. Researchers used MRI scans to measure heart fat and function. The goal was to see if this treatment could lower heart risks beyond just controlling blood sugar.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GLP-1 receptor agonist (exenatide/BYETTA)
What this could lead to: If successful, this could show that GLP-1 drugs improve heart function and reduce dangerous fat around the heart in obese diabetics.
What could go wrong: This is a small, completed Phase 3 trial with only 44 participants, so results may not apply to everyone. The study focused on heart imaging changes, not long-term health outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetes mellitus Obesity obesity disorder type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES OBESITY

Contacts and locations

Locations

Assistance Publique Hopitaux de Marseille

Marseille, 13354, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.